Vyome Holdings, Inc (HIND): Nasdaq/NYSE listing notice — ReShape Lifesciences receives Nasdaq delisting notice; intends to appeal

Vyome Holdings, Inc

Nasdaq determined to delist RSLS for failing to meet $2.5M stockholders' equity requirement by May 27, 2025 extension deadline.
Trading will be suspended June 6 unless the company appeals by June 4; a Form 25-NSE will then remove securities from listing.
Company intends to appeal to a Nasdaq hearings panel, which would stay suspension pending decision.
No assurance hearings panel will grant continued listing or that compliance with listing rules can be maintained.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vyome Holdings, Inc received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

May 28, 2025, ReShape Lifesciences Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that Nasdaq has determined to delist the Company’s securities from Nasdaq. On November 25, 2024, Nasdaq notified the Company that it did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5550(b). However, Nasdaq granted the Company’s request for an extension until May 27, 2025 to comply with this requirement. Nasdaq has determined that

View on SEC.gov

3 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001104659-25-054856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.